Eliav Barr - Articles and news items

Merck logo

Merck to present new data for investigational hepatitis C treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress™ 2014

Industry news / 24 March 2014 / Merck

Merck announced that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver…

Merck logo

Merck announces presentation of interim data from study of investigational combination of HCV therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases annual meeting

Industry news / 2 November 2013 / Merck

Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied…

Merck logo

Merck to present updated interim data from Phase II trial

Industry news, News / 23 April 2013 / Merck

Merck announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial…

Merck logo

Merck enters agreement with Bristol-Myers Squibb

Industry news, News / 22 April 2013 / Merck

Agreement to conduct a Phase II clinical trial evaluating combination of investigational oral candidates MK-5172 and daclatasvir for chronic hepatitis C…

Merck logo

Merck to present new data on VICTRELIS® (boceprevir)

Industry news, News / 8 April 2013 / Merck

VICTRELIS® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection…

Merck logo
Merck logo

Merck announces initiation of clinical development collaboration with Roche

Industry news, News / 15 December 2011 / Merck

New clinical trial will evaluate an investigational therapeutic regimen with VICTRELIS™ (boceprevir)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...